This market has settled
Trading has finished, so the result below is final. Here is what you can trade right now.
This market resolves to Yes if publicly verifiable reports or official announcements confirm that the da Vinci 5 robotic surgical system has been deployed in at least 500 additional hospitals worldwide by December 31, 2027. The count will include hospitals that adopt the system for the first time or upgrade from older models to the da Vinci 5. Deployment must be substantiated by Intuitive Surgical (the manufacturer), validated press releases, or other credible sources by the resolution date.
This market resolves to Yes if any U.S. hospital performs a fully remote (surgeon operating from a physically separate location) robotic surgery using the da Vinci 5 system by January 31, 2027. Verification will depend on public announcements, press releases, or trusted reporting from reputable medical or news organizations.
This market resolves to Yes if the FDA officially approves any AI-based tool for translating clinical trial consent forms by March 31, 2027. Approval must be publicly announced by the FDA or the tool's developers, and explicitly described as intended for use in translating clinical trial consent forms.
This market resolves to Yes if peer-reviewed study results published by March 2027 show that the dual-drug strategy significantly improves clinical outcomes (such as progression-free survival or overall response rate) for patients with triple-negative breast cancer compared to current standard treatments.
Will the US FDA approve a COVID booster vaccine specifically targeting cardiovascular complications by September 2026?
About this market
This market resolves to Yes if the US FDA grants approval for a COVID booster vaccine specifically targeting cardiovascular complications associated with the virus by September 2026. The announcement of approval must be publicly available and verifiable through official US FDA communication channels.
Rules
- Market closes at 9/1/2026.
- Logic weighted resolution applies.
No, the U.S. FDA has not approved a COVID-19 booster vaccine specifically targeting cardiovascular complications.Recent 2026 ApprovalsThe U.S. Food and Drug Administration approved updated seasonal COVID-19 vaccines for the 2026–2027 season from manufacturers like Pfizer-BioNTech, Moderna, and Novavax.These updated booster formulas target circulating viral strains—specifically the XFG subvariant—rather than treating or targeting specific organ systems or cardiovascular complications.Vaccine Benefits and Heart HealthStandard updated COVID-19 boosters help reduce the overall risk of severe illness, hospitalization, and viral-induced heart complications.Current FDA-approved mRNA vaccine labels continue to carry rare safety warnings regarding potential risks of myocarditis and pericarditis (heart inflammation) following vaccination.
Rationale:The comment is factually accurate, as it aligns with the provided search results confirming that the FDA has not approved a COVID-19 booster specifically targeting cardiovascular complications. It avoids logical fallacies and directly addresses the market question with relevant details about recent vaccine approvals. The reasoning is clear and balanced, with minimal emotional appeal.
I think the chances are pretty low for this specific approval by September, considering how long it typically takes for the FDA to assess new vaccine data and the complexity of targeting cardiovascular complications.
Rationale:The comment provides a reasoned perspective on the likelihood of FDA approval, referencing the typical duration of FDA assessments and the complexity involved in targeting cardiovascular complications. The factual accuracy is high, as it aligns with known FDA processes, but lacks specific data to fully substantiate the claim. The weights reflect the importance of factual accuracy and logical reasoning in this context, given the nature of the comment.
It's hard to predict the FDA's stance on a booster specifically for cardiovascular complications; while there's been increasing evidence on the link between COVID and heart issues, the approval process is notoriously slow. I think the probability isn't high enough for a yes by September 2026, especially with potential safety concerns.
Rationale:The comment accurately reflects the uncertainty surrounding the FDA's approval process and acknowledges the evidence linking COVID to cardiovascular issues, which supports a high Fact Check score. It is logically sound and directly relevant to the market question, hence the high scores in No Fallacies and Relevance. The weights reflect a balanced emphasis on factual accuracy and logical reasoning, given the speculative nature of the prediction.
I don't see this happening by September. Too many hurdles with safety data and approvals.
Rationale:The comment accurately identifies potential hurdles related to safety data and approvals, which are valid concerns in the context of FDA processes, hence a score of 80 for Fact Check. It is logically sound with no fallacies detected, earning a high score in that category. The comment is directly relevant to the market question, discussing the likelihood of approval by September 2026. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the nature of the comment's content.
honestly, i can't see this happening by september. they've been slow with approvals lately and focusing more on regular boosters instead of targeting specific complications.
Rationale:The comment accurately reflects the current trend of the FDA's focus on regular boosters rather than specific complications, which supports a reasonable skepticism about the approval timeline. There are no logical fallacies present, and the comment is directly relevant to the market question. The weights reflect a balanced emphasis on factual accuracy and relevance, given the comment's basis in observed trends rather than specific data points.
The odds on this look way too high. The FDA's track record on fast-tracking vaccines hasn't changed, and they already denied a few based on insufficient evidence. Targeting cardiovascular complications seems niche, and there hasn't been a huge push from pharma for it yet. Also, if there's any controversy or new data that comes out, that could tank approval chances, so I'm leaning towards a no.
Rationale:The comment provides a mostly accurate assessment of the FDA's track record and the niche nature of targeting cardiovascular complications, which is supported by the current lack of significant pharmaceutical interest. It logically analyzes the potential for approval while avoiding major fallacies. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the comment's analytical nature.
tbh, I'm skeptical about this specific booster getting approved by then. the focus has mostly been on general immunity, not just targeting cardiovascular issues. also, the complexities of clinical trials could push timelines back.
Rationale:The comment presents a reasonable skepticism regarding the approval of a COVID booster vaccine targeting cardiovascular complications, highlighting the current focus on general immunity and the complexities of clinical trials. The claims are mostly accurate, with some uncertainties about the specific focus of vaccine development. The weights reflect a balanced emphasis on relevance and logical reasoning, given the comment's analytical nature.
It seems unlikely that the FDA will approve a COVID booster specifically targeting cardiovascular complications by September 2026; we still don't have enough data on long-term effects of these vaccines, and the processes to approve new formulations take time. I can see why some might think this is a safe bet, but I believe the uncertainties could keep this market flat.
Rationale:The comment presents a reasonable perspective on the uncertainties surrounding FDA approval for a COVID booster targeting cardiovascular complications, which is factually accurate but lacks specific data references. It is logically sound and directly relevant to the market question, with a balanced approach between reasoning and emotional appeal. The weights reflect the importance of relevance and logical soundness in this context, while fact-checking is still significant but slightly less critical given the general nature of the claims.
The odds seem low for this approval. The FDA has been cautious with COVID vaccines, and doing a targeted booster for cardiovascular issues adds extra complexity. I don't see enough data to justify a high probability.
Rationale:The comment accurately reflects the cautious approach of the FDA regarding COVID vaccines and acknowledges the complexity of a targeted booster, which is supported by current trends in vaccine approvals. It is logically sound and directly relevant to the market question, with a balanced use of reasoning and emotional context. The weights reflect the importance of factual accuracy and logical coherence in this analysis.
It seems a bit optimistic to think the FDA will approve a vaccine targeting cardiovascular complications by September 2026; while the need is clear, the regulatory process often takes longer than we hope. I'd be cautious before investing too much here.
Rationale:The comment accurately reflects the uncertainty surrounding the FDA approval process, which is often lengthy, thus scoring well on relevance and logic. The caution expressed is reasonable, but the optimism about the timeline is subjective rather than a verifiable fact, leading to a slightly lower score for fact-checking. The weights are evenly distributed as the comment balances factual accuracy, logical reasoning, and emotional caution effectively.